Form 483

InvaGen Pharmaceuticals, Inc. Form 483, 2010-11-10

FDA issued a Form 483 to InvaGen Pharmaceuticals, Inc. on 2010-11-10 with 8 public-safe observations.

483· Form 483 issued8 observations

InvaGen Pharmaceuticals, Inc. · Hauppauge, United States · Issued November 10, 2010

Overview

  • 8 public-safe observations are available for this inspection.
  • 8 structured CFR citations are represented.
  • 1 investigator is tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

10 Nov 2010
21 CFR 211.22(d)

Procedures not in writing, fully followed

Cited by Kevin A Gonzalez

10 Nov 2010
21 CFR 211.80(a)

Procedures To Be in Writing

Cited by Kevin A Gonzalez

10 Nov 2010
21 CFR 211.115(a)

Reprocessing procedures not written or followed

Cited by Kevin A Gonzalez

10 Nov 2010
21 CFR 211.160(b)(2)

In-process samples representative, identified properly

Cited by Kevin A Gonzalez

10 Nov 2010
21 CFR 211.165(c)

Sampling and testing plans not described

Cited by Kevin A Gonzalez

Inspected site

IPInvaGen Pharmaceuticals, Inc.Hauppauge, United States

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.115(a)Cited across public-safe Form 483 observations1x
21 CFR 211.160(b)(2)Cited across public-safe Form 483 observations1x
21 CFR 211.165(c)Cited across public-safe Form 483 observations1x
21 CFR 211.186(b)(9)Cited across public-safe Form 483 observations1x
21 CFR 211.198(a)Cited across public-safe Form 483 observations1x
21 CFR 211.22(d)Cited across public-safe Form 483 observations1x
21 CFR 211.80(a)Cited across public-safe Form 483 observations1x
21 CFR 314.81(b)(1)(ii)Cited across public-safe Form 483 observations1x

Source document

PDF
PDF available

Form 483 source document

The source document is available to authorized Atlas users.

Full 483 report

Get the verbatim text of all 8 observations

The source PDF and every observation in full, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere